Anti-FOLR1 Immunoconjugate Dosing Regimens
AssigneeImmunoGen, Inc.
InventorsKelli RUNNING, Robert A. MASTICO, James J. O'LEARY, Olga AB, Beni WOLF
Life of this patent
Estimating the term…
Abstract
Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
Claims26
A method for treating a human patient having cancer comprising administering to the patient an effective dose of an immunoconjugate that binds to FOLR1 polypeptide, wherein the administration produces a C max of about 100-150 μg/mL.
A method for treating a human patient having cancer comprising administering to the patient an effective dose of an immunoconjugate that binds to FOLR1 polypeptide, wherein the immunoconjugate is administered at a dose of about 6 mg/kg about once every week.
A method for treating a human patient having cancer comprising administering to the patient an effective dose of an immunoconjugate that binds to FOLR1 polypeptide, wherein the immunoconjugate is administered at a dose of about 6.5 mg/kg about once every week.
The method of any one of claims 1-16 and 18-25, wherein the cancer is ovarian cancer and wherein the administration results in a decrease in CA125.
Dependencies are inferred from the claim text.